The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. The metric has seen a significant gain of 139.01% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -46.50%. Over the past 30 days, the price of AVTX has fallen by 389.86%. And in the last five days, it has surged by 372.83%.
Avalo Therapeutics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $1130.40 on 06/23/23, while the lowest price for the same period was registered at $3.95 on 01/17/24.
52-week price history of AVTX Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Avalo Therapeutics Inc’s current trading price is -98.08% away from its 52-week high, while its distance from the 52-week low is 450.62%. The stock’s price range during this time has been between $3.95 and $1130.40. The trading volume for the Healthcare sector company’s shares reached about 31.61 million for the day, which was higher than the average daily volume of 98060.0 over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Avalo Therapeutics Inc (AVTX) has experienced a quarterly rise of 74.28% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 17.40M and boasts a workforce of 19 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 10.05, with a change in price of -2.80. Similarly, Avalo Therapeutics Inc recorded 426,988 in trading volume during the last 100 days, posting a change of -11.41%.
AVTX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for AVTX stands at 0.53. Similarly, the long-term debt-to-equity ratio is also 0.46.
AVTX Stock Stochastic Average
Today’s raw stochastic average for Avalo Therapeutics Inc over the last 50 days is 58.27%.This indicates a increase from the raw stochastic average of the past 20 days, which was 57.85%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 33.47% and 28.07%, respectively.
